Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932

Study (n=9229) found maintenance vincristine/dexamethasone pulses every 12 weeks (VCR/DEX12) was associated with similar 5-year disease-free and overall survival results to 4-week pulses; it has since been incorporated into frontline COG B-ALL trials to decrease therapy burden.

Journal of Clinical Oncology